Interventional Glaucoma

Mark Gallardo, MD, reports 12-month outcomes of iStent inject® combined with cataract surgery in a predominantly Hispanic patient population with mild to moderate open-angle glaucoma (OAG) and comorbid cataract.

Hisaharu Suzuki, MD, PhD, provides insight on how a handpiece maintains the anterior chamber stability even when occlusion occurs, suggesting its usefulness for a safe and efficient surgery.

Basil Williams, Jr., MD, reports on the association between development of elevated intraocular pressure and numerous commonly performed vitreoretinal treatments.

A new report has found that glaucoma specialists’ procedure of choice has changed as a result of the COVID-19 pandemic.

Although minimally invasive procedure gives hope, additional research is required.

According to iSTAR Medical, the STAR-V study will investigate the device in 350 patients with primary open angle glaucoma.

New strategies are needed to rethink how we treat glaucoma to do more than just manage eye pressure—to actually restore vision by promoting the survival of retinal ganglion cells and their axons.

There’s no shortage of diet programs—Paleo, Mediterranean, intermittent fasting—all claiming to be the best option for a healthy life. Research has shown that poor lifestyle choices, including unhealthy diets, contribute to many diseases and that simply adhering to good nutrition can even prevent some health issues.

Landmark randomised controlled trials have advanced the understanding and treatment of glaucoma.

Pressure-dependent optic nerve disease, retinal disease.

Two trials examine factors affecting the risk of disease.

The glaucoma treatment company rebrands to align more closely with goals and direction of the company.

MIGS drainage device offers hope for challenging cases.

Exploring subtleties helps ophthalmologists understand postop surprises, drug reactions.

Knowledge of tools used in data interpretation helps clinicians trust accuracy of findings.

Measurements from multiple studies show benefits of rho-kinase inhibition.

Increased access is key to preventing disease progression in patients.

Minimally invasive glaucoma surgery (MIGS) is appealing to glaucoma patients and surgeons; however, it should not be adopted without further high-quality research and careful reporting. Selection of the appropriate treatment for individual patients must be evidence based.

Implandata received FDA Breakthrough Device Designation for its Eyemate-SC in April and now has CE Mark approval in the European Union.

Visible-light optical coherence tomography proves valuable in studies.

Details enhance knowledge of biological pathways that contribute to disease pathogenesis.

Physicians are left to determine which treatments can offer patients best outcomes.

Retrospective review highlights the sustained efficacy of combination procedure.

Two randomised controlled trials, EMGT and UKGTS, have examined the factors affecting the risk of glaucoma progression. Global target IOPs are not the best option for all patients.

Option could prove to enhance safety for both patients and staff.